[1] NICE guidance (NG28) recommends GLP-1 receptor agonists like semaglutide for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is ineffective, not tolerated, or contraindicated The person has a BMI of 35 kg/m or higher (adjusted for ethnicity) and specific psychological or medical problems associated with obesity BMI is lower than 35 kg/m but insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Ozempic is available in pre-filled, multi-dose pens delivering 0.25 mg, 0.5 mg, 1 mg, or 2 mg doses
We recently shared a behind the scenes look at this process, because clients deserve to know exactly what goes into their bodies and who is handling it
May provide additional metabolic benefits, including improved beta-cell function, reduced glucagon secretion, delayed gastric emptying, and increased satiety 22
In some cases, people have serious side effects because they have a health problem that increases their risk